Drug intelligence / Profile preview

SD-D01

Development stage: Preclinical
Lead developer: Sinedore Medicine
Modality: Small Molecules

Overview

SD-D01 is a small molecule drug candidate currently under development by Sinedore Medicine. It is specifically categorized within the company's pipeline as a pediatric formulation, aimed at addressing therapeutic needs in children. As of early 2024, the program is in the lead optimization phase of preclinical development. While the specific biological target and primary therapeutic indication have not been publicly disclosed, the project represents Sinedore's commitment to developing age-appropriate medications for pediatric populations.

Targets

KCNQ2/3 (Potassium voltage-gated channel subfamily KQT member 2/3)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on SD-D01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-D01.

Explore the full profile